27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Social isolation and loneliness are associated with significant negative impacts on mental and physical health, including heart disease, stroke, depression, cancer, and dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Problem Definition: Grocery retailers increasingly fulfil online orders from existing stores rather than from dark stores (dedicated warehouses/fulfilment centers). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In today’s fast-changing business environment, it’s extremely important to be able to respond to client needs in the most effective and timely manner. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Medicare and Medicaid provide health coverage to millions of Americans, including older adults, people with disabilities, low-income families, children, and individuals with complex medical and social needs. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our results showed that XGBoost was the top-performing modeling approach for each domain. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We derive a class of composite estimators of small-area quantities that exploit spatial (distance-related) similarity. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study suggests that although ED staff expressed confidence regarding symptom management in palliative care, they lacked understanding of the patients in whom a palliative approach could be applied and sought further education in areas, such as end-of-life communication and ethical issues. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Intravenous neuronal tau-targeted T807-modified novel biomimetic nanosystems are a promising clinical candidate for the treatment of AD. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The FDA converted lecanemab (Leqembi) from accelerated to full traditional approval after the Phase 3 Clarity AD trial (1,795 patients) confirmed it slowed cognitive decline, making it the first amyloid-targeting antibody to reach full approval for Alzheimer's. The drug carries a boxed warning for ARIA, brain swelling or bleeding that is usually detected on routine MRI and is more common in people with two copies of the ApoE ε4 gene or those on blood thinners. 3 key findings →
Design: regulatory decision Evidence: moderate
Full summary, score breakdown and related studies → Original source
Information technology is bringing fundamental changes to many U.S. industries. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Existing literature analyzing the choice of received long-term care by frail elderly (65 years) predominantly focuses on physical and psychological conditions of elderly people as factors that influence the decision for a particular type of care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Pericytes are cells in the blood-brain barrier that degenerate in Alzheimer's disease (AD), a neurological disorder associated with neurovascular dysfunction, abnormal elevation of amyloid β-peptide (Aβ), tau pathology and neuronal loss. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Foreword. Preface C.R. Snyder. 1. Physical Illness and Depression in Older Adults: An Introduction D.R. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Following an anonymous 2021 whistleblower petition to the FDA alleging manipulated research underlying the Alzheimer's drug simufilam, PLOS ONE conducted its own investigation and retracted five papers co-authored by Hoau-Yan Wang, some of them co-authored with a Cassava Sciences executive, after finding that background patterns in blot images appeared 'more similar than would be expected for data obtained in independent experiments.' 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
I develop a dynamic oligopoly model to study the evolution of retail grocery: Grocery chains expand at the expense of independent local stores. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aims to test a model that investigates the impact of self-store image congruency on the in-store shopping experience in the context of grocery retail setting, which in turn, explain and predict different facets of consumer behavior, including consumer satisfaction, consumer engagement, and store attachment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our pre-experiments found that the brain circRNA sequence profiles and gut microbiota in AD-like mice were changed, as circNF1-419 could enhance autophagy to ameliorate senile dementia in AD-like mice, so we conclude that there might some connections between circRNA and gut microbiome. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Blood-brain barrier (BBB) defects and cerebrovascular dysfunction contribute to amyloid-β (Aβ) brain accumulation and drive Alzheimer disease (AD) pathology. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
On January 31, 2024, Biogen announced it would discontinue development and sales of Aduhelm (aducanumab) and end the mandatory post-approval ENVISION confirmatory trial, redirecting resources to lecanemab (Leqembi) and other pipeline drugs, including two tau-targeting compounds (BIIB080, BIIB113). 3 key findings →
Design: company announcement
Full summary, score breakdown and related studies → Original source
In this case, Super Value Grocery Store in Nassau, Bahamas experiences a rapid decline in sales. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
CMS's national policy covers FDA-approved anti-amyloid monoclonal antibodies (such as lecanemab and donanemab) for Medicare patients with a documented diagnosis of mild cognitive impairment or mild Alzheimer's dementia and confirmed amyloid pathology, under a framework called 'Coverage with Evidence Development.' 3 key findings →
Design: coverage determination
Full summary, score breakdown and related studies → Original source
Evidence: low
Full summary, score breakdown and related studies → Original source
Naturally occurring axonal pruning and neuronal cell death help to sculpt neuronal connections during development, but their mechanistic basis remains poorly understood. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Memory function often declines with age, and is believed to deteriorate initially because of changes in synaptic function rather than loss of neurons. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Late-onset Alzheimer's disease (LOAD) risk is strongly influenced by genetic factors such as the presence of the apolipoprotein E ε4 allele (referred to here as APOE4), as well as non-genetic determinants including ageing. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →